How to spot a fake Mounjaro pen in India: a step-by-step authenticity check.

Why this guide exists

In April 2026, the Haryana State Food and Drug Administration intercepted a vehicle in DLF Phase-4, Gurugram, and seized 262 vials of counterfeit injections labelled as "Mounjaro" (tirzepatide), valued at over ₹70 lakh. Subsequent raids led police to a flat in Sector 62, Gurugram, where the alleged mastermind — Avi Sharma — was operating a one-room manufacturing unit with a refrigerator and a deep freezer, using 3D-printed cartons, labels, and leaflets to mimic Lilly's packaging. He is also alleged to have produced 15–16 vials of an unapproved tirzepatide product under his own brand "Toneup", which were sold through IndiaMART to buyers in Delhi, Hyderabad, and other cities.

Amandeep Chauhan, the Gurugram district drug controller, told reporters that the counterfeits were spotted because the carton blues and purples were the wrong shade, the typography did not match, and the printed pen illustration on the carton was "blurred, dark and shorter" than the genuine one. Charges were registered under Sections 17B, 27(a), and 27(c) of the Drugs and Cosmetics Act, 1940.

Eli Lilly and Company (India) confirmed on 30 April 2026 that the seized products "were not manufactured by Lilly and did not originate from Lilly's authorised and verified supply chain". Winselow Tucker, President and General Manager of Lilly India, said the company "will continue to take steps to protect patients from the risks of counterfeit and other unsafe products worldwide". Crucially, Lilly clarified that its patented tirzepatide molecule is now marketed in India under two brand names — Mounjaro (sold directly by Lilly) and Yurpeak (distributed by Cipla under a partnership announced 23 October 2025).

Apollo Pharmacy is not named in the Haryana FDA action. However, on Apollo's own product Q&A page for the Mounjaro 5 mg KwikPen, a customer has publicly posted that a pen bought from "a nearby Appolo pharmacy" looked fake — "The components that is storing the medicine is made up of some cheap plastic and not glass material". Apollo's published reply asserts the pen was authentic but tells the customer not to use it until verified, and to bring the pen and invoice to a store for pharmacist review. That single, unverified complaint has not, as of this writing, been escalated to a CDSCO recall, a state FDA action, or any news report. We mention it because it sets the broader point: even where "trusted" channels are involved, the public record now contains both confirmed counterfeit seizures and at least one unresolved customer doubt — and verification has become the patient's job.

This guide gives you six visual checks to run on the pen and carton, how to read the batch number, how to verify directly with Lilly India, what to do if you suspect or confirm a fake, and what India's regulatory framework can and cannot do for you. If terms like KwikPen, batch number, cold chain, or Schedule H are new, our GLP-1 dictionary covers them.

The 6-point visual authenticity check

The authentic Indian-market Mounjaro KwikPen carries a specific look. Lilly India and the Haryana FDA have publicly cited several of the differences below; others are drawn from EMA product information (Lilly produces all global Mounjaro stock). Where a "tip" was sourced only from social media and not corroborated by Lilly or a regulator, we have omitted it.

The outer carton

Authentic: Stiff, smooth white paperboard with crisp four-colour offset printing. The brand mark "Mounjaro®" and Lilly's red script logo are sharply defined; the dose strength (2.5, 5, 7.5, 10, 12.5, or 15 mg) appears in a coloured band that differs by strength. Hindi text and Lilly India's Gurugram address appear on the side panel of the Indian-market carton.

Counterfeit signs: The Haryana FDA found the counterfeit Mounjaro cartons had "different shades of blue and purple" from genuine ones, mis-aligned text, and a pen illustration that was "blurred, dark and shorter" than the original. Soft, flimsy paperboard, fuzzy edges on the logo, mis-registered colours (a faint ghost outline next to text), missing Hindi text, or absence of the Indian importer block all argue against authenticity.

Holographic and tamper-evident features

Authentic: The end-flaps of the carton are factory-glued and torn open on first use; once opened, they cannot be re-glued cleanly. Indian-market Mounjaro cartons are sealed at both ends; the QR / 2D Data Matrix code is printed directly on the carton — it is not a sticker.

Counterfeit signs: Re-glued flaps, visible adhesive residue, slightly oversized flaps (a sign of repackaging), a QR code applied as a sticker, or any tamper-evident seal that peels off intact. Lilly's official anti-counterfeit guidance lists "packaging that appears tampered with or damaged" as a primary red flag.

The pen body — KwikPen vs single-dose pen

This is the single biggest source of patient confusion in India. The Mounjaro KwikPen is a multi-dose, single-patient-use pre-filled pen — each KwikPen holds 2.4 mL of solution and delivers four weekly doses at the labelled strength (e.g. 4 × 5 mg). It has a dose knob at the end and a small dose-counter window. The single-dose pre-filled pen (sold as "Mounjaro 2.5 mg / 5 mg PFP Injection" in 0.5 mL or 0.6 mL on Indian pharmacy listings) and the single-dose vial are also Lilly products but deliver one dose only.

Authentic KwikPen: Smooth, semi-matte plastic body, even weight, no audible rattle, dose window shows clear black numerals against a white background, dose knob clicks crisply, the cartridge inside is glass.

Counterfeit signs: The Apollo customer complaint described "cheap plastic" components "not glass" inside. Lilly's global guidance flags pens that "look or feel different from previous genuine ones" and pens whose dose knob is loose or detaches — the exact defect the UK MHRA found in counterfeit 15 mg Mounjaro KwikPens with batch number D873576 in February 2025.

Label printing

Authentic: Sharp single-font label (Lilly uses a consistent corporate typeface across global SKUs). The batch number ("LOT" or "B. No.") and expiry ("EXP" or "Exp.") are printed on the same line or in tightly aligned blocks on both carton and pen label, with identical values. Ink is dense, jet-black, and does not smudge under a dry thumb.

Counterfeit signs: Mixed fonts, uneven letter spacing, batch and expiry values that do not match between pen and carton, ink that smears, or stickers placed over original printing.

The leaflet / Instructions for Use

Authentic: Glossy, thin pharmaceutical-grade paper, multi-fold, includes English and at least one regional Indian script. Carries Lilly India's Gurugram address, the manufacturing-site address (Mounjaro is currently manufactured outside India and imported), the CDSCO import licence number, and pictograms matching the EMA product information.

Counterfeit signs: Photocopy-quality print, single-language English-only leaflet, missing import licence number, missing manufacturer address, or pictograms that look hand-redrawn. The Haryana FDA noted that the counterfeit Mounjaro leaflets in the Gurugram case were printed using consumer-grade equipment and showed "clear inconsistencies in colour, typography, text alignment, and pen illustrations".

Serialisation: barcode and 2D Data Matrix

Under the Drugs (Eighth Amendment) Rules, 2022, manufacturers of the top 300 brands listed in Schedule H2 must carry a QR or barcode on the primary or secondary pack from 1 August 2023. Mounjaro launched in India on 20 March 2025 and is not on the original Schedule H2 list; however, Lilly applies a 2D Data Matrix code to Mounjaro cartons globally containing the GTIN, batch number, expiry, and a unique serial number. On Indian-market cartons you should expect to see (a) a printed 2D Data Matrix code, (b) the GS1 human-readable line beneath it (GTIN / batch / expiry / serial), and (c) a separate linear barcode.

How to read a Mounjaro batch number

Lilly uses a global lot-numbering convention. The UK MHRA's February 2025 alert disclosed one genuine lot — D873576 for the 7.5 mg KwikPen — because counterfeiters had applied that same number to a 15 mg pen. Lot numbers begin with a letter and are followed by six digits; they are printed at three places on every authentic pack: on the carton end-flap (next to "LOT" or "B. No." and "EXP"), on the foil pouch of the pen if present, and on the pen label itself. All three must match exactly. If any of the three is missing, smudged, or mismatched, the pack should be treated as suspect.

For Indian-market product, you should also see:

• "Imported and marketed by Eli Lilly and Company (India) Pvt. Ltd., Plot No. 92, Sector 32, Institutional Area, Gurugram 122001" on the carton
• The CDSCO import registration number on the carton or leaflet
• The MRP in Indian rupees. At the KwikPen's August 2025 launch, Lilly set prices at ₹14,000 (2.5 mg), ₹17,500 (5 mg), ₹22,000 (7.5 mg and 10 mg), and ₹27,500 (12.5 mg and 15 mg) per pen. After the September 2025 GST reduction on vial-form tirzepatide, online pharmacy listings now commonly show MRPs of ₹13,125 (2.5 mg) up to ₹25,781 (15 mg). Both ranges are legitimate; an MRP outside this corridor is not.
• Either Mounjaro or Yurpeak as the brand name. Yurpeak (Cipla-distributed, launched December 2025) is also genuine Lilly-manufactured tirzepatide; its packaging carries Cipla branding alongside Lilly.

Grey-market / parallel-imported product is, by definition, not Indian-market product. US-sourced Mounjaro pens bear NDC numbers and FDA-format black-box warnings; UAE-sourced pens carry MoH UAE registration; Turkish stock carries Turkish-language labelling. None will display the Lilly India Gurugram address, an Indian MRP, or a CDSCO import licence number. A pen bought in India that does not bear the Indian importer block is, at best, a parallel import (not approved for resale in India) and at worst counterfeit.

Lot and expiry pairing: An authentic Mounjaro KwikPen has 24-month shelf-life from manufacture; a pen showing a lot number whose expiry is more than 24 months from the apparent manufacture date — or whose expiry has been physically over-stickered — is suspect.

Mounjaro batches flagged in India to date

This list is point-in-time and limited to entries we could trace to a named regulator, a named Lilly statement, or a named mainstream news source. For updates, monitor the CDSCO Alerts page (cdsco.gov.in/opencms/opencms/en/Notifications/Alerts/), state FDA news tickers (Maharashtra FDA at fda.maharashtra.gov.in), and Eli Lilly India press releases on in.lilly.com.

Verifying directly with Eli Lilly India

The following information was confirmed against Lilly's own India websites in May 2026.

What to have ready before you call or email:

1. The exact batch / lot number as printed on the carton and the pen.
2. The expiry date as printed on the carton and the pen.
3. The name of the pharmacy (and its store code, if a chain), the purchase date, and a scan of the GST tax invoice.
4. Clear photographs of the carton (front, back, both side panels), the pen, the leaflet, and the QR / Data Matrix block.
5. A short, factual description of what looks wrong (do not embellish; stick to what you can see and feel).

"My name is [____]. I would like to report a suspected counterfeit Mounjaro KwikPen. Strength [__] mg. Lot number [__]. Expiry [__]. Purchased from [pharmacy, branch, city] on [date]. I have the original carton, pen and GST invoice. I am [not] currently using the pen. Please open a product-complaint case and tell me the reference number and the next step." — Suggested script when calling 1800-123-0021

Expected response. Lilly India's patient-services convention is to log the complaint, issue a case reference, request photographs by email at lillycares_india@lilly.com, and forward the sample to its India quality team. Lilly has not published a service-level commitment for India response times. A legitimate Lilly reply will (a) come from a lilly.com address, (b) reference your case number, (c) ask only for photographs and the invoice — never for a payment, a UPI ID, or your bank details. Any "Lilly India" reply that requests money or shares a non-lilly.com link should be treated as a phishing attempt and reported back to the same helpline.

If you suspect or confirm a fake — the action sequence

Why "trusted pharmacy" is no longer a safety guarantee

The Gurugram bust is instructive. Avi Sharma is alleged to have bought two genuine Mounjaro pens on prescription, photographed the packaging, used a 3D printer to replicate cartons, labels, and leaflets, sourced research-grade tirzepatide and empty pen cartridges online, mixed and filled them in a one-room flat in Sector 62, and then pitched the result through IndiaMART and to wholesalers in Delhi's Bhagirath Palace market. The Haryana FDA traced six injections sold in Hyderabad alone. None of the chain names anchoring this guide — Apollo Pharmacy, Tata 1mg, PharmEasy, Netmeds — has been linked by a regulator to the Sharma operation; but the channels Sharma used (IndiaMART, informal wholesale, individual buyers) demonstrate how a pen entering distribution one rung above any retail pharmacy can become indistinguishable from genuine stock at the till.

Three structural weaknesses in India's pharma chain make this kind of substitution possible:

1. Distributor-level substitution. Stockists are licensed and inspected but are not subject to a unified track-and-trace system. A pen received from an unauthorised secondary stockist will reach a retail pharmacy in the same plain shipper as authorised stock.
2. Cold-chain breaks enable repackaging. Mounjaro must be stored at 2–8 °C. A break in cold chain — common in informal redistribution — gives a counterfeiter the cover of "repackaging" damaged stock into convincing cartons.
3. Online-marketplace seller fraud. IndiaMART, Telegram and WhatsApp listings sit outside the Drugs and Cosmetics Act's pharmacy-licensing perimeter; verifying a seller's drug-licence on these channels is, in practice, the buyer's job. These channels exist for buyers avoiding the consultation step — if that's you, it is faster and safer to get a legal prescription instead; a video consult costs as little as ₹300–₹900.

Quick reference: the checklist

The 6 visual checks, in order:

1. Carton. Stiff paperboard, sharp blues and purples, crisp pen illustration, Lilly India Gurugram address, Hindi side panel.
2. Tamper seal. Factory-glued end-flaps; QR printed (not stuck).
3. Pen body. Smooth semi-matte plastic, glass cartridge visible, crisp dose-knob click.
4. Label. Identical batch and expiry on carton and pen, dense black ink, no smudging.
5. Leaflet. Glossy multi-fold, English plus regional script, CDSCO import licence number visible.
6. Serialisation. 2D Data Matrix printed on carton, GS1 human-readable line beneath.

Key contacts:

• Eli Lilly India patient helpline: 1800-123-0021
• Lilly India switchboard: +91-124-4753000 / 01
• Lilly India email: lillycares_india@lilly.com
• CDSCO complaint email: dci@nic.in, enforcecell.div@cdsco.nic.in
• CDSCO PRO toll-free: 1800-11-1454
• e-Daakhil (consumer court online): https://edaakhil.nic.in
• Maharashtra FDA grievance: jchq.fda-mah@nic.in

The 5-step "if you suspect a fake" action sequence:

1. Stop using; refrigerate and preserve carton + pen + invoice + leaflet.
2. Call Lilly India 1800-123-0021 and obtain a case reference.
3. Return to the dispensing pharmacy; demand refund or replacement; get any refusal in writing.
4. Email CDSCO (dci@nic.in) and your state FDA with photos and invoice.
5. If consideration paid exceeds your tolerance for write-off, file on edaakhil.nic.in within two years.

What would change this guidance

Three benchmarks would meaningfully shift the burden of verification away from patients and back to the system:

• Lilly launching an India-specific scan portal. At that point, helpline verification becomes optional rather than mandatory.
• CDSCO's DDRS going live with mandatory pharmacy scan-out at the point of dispensing. At that point, the burden shifts back from patient to system.
• Mounjaro being added to a revised Schedule H2. At that point, the QR code on the pack becomes legally enforceable rather than a Lilly-voluntary marking.

None of these has happened as of 27 May 2026. Until they do, the five minutes per refill that verification takes is, unfortunately, part of the cost of being on therapy in India. One more reason to take it seriously: a sub-potent counterfeit doesn't announce itself — it shows up as your weight loss quietly stopping and the food noise coming back, which most people misread as their body adapting. If that's the symptom you're chasing, run the checks in our Mounjaro plateau guide — a fake pen is one of the five causes of a stall, and it's the one this article rules in or out.